Cargando…

Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy

This real-world analysis was performed on administrative databases to evaluate characteristics, therapies, and related economic burden of glaucoma in Italy. Adults with at least 1 prescription for ophthalmic drops (ATC class S01E: antiglaucoma preparations, miotics) during data availability period (...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Valentina, Formica, Dario, Piergentili, Benedetta, Rossetti, Luca, Degli Esposti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001280/
https://www.ncbi.nlm.nih.gov/pubmed/36900638
http://dx.doi.org/10.3390/healthcare11050635
_version_ 1784904096839368704
author Perrone, Valentina
Formica, Dario
Piergentili, Benedetta
Rossetti, Luca
Degli Esposti, Luca
author_facet Perrone, Valentina
Formica, Dario
Piergentili, Benedetta
Rossetti, Luca
Degli Esposti, Luca
author_sort Perrone, Valentina
collection PubMed
description This real-world analysis was performed on administrative databases to evaluate characteristics, therapies, and related economic burden of glaucoma in Italy. Adults with at least 1 prescription for ophthalmic drops (ATC class S01E: antiglaucoma preparations, miotics) during data availability period (January 2010−June 2021) were screened, then patients with glaucoma were included. First date of ophthalmic drops prescription was the index date. Included patients had at least 12 months of data availability before index-date and afterwards. Overall, 18,161 glaucoma-treated patients were identified. The most frequent comorbidities were hypertension (60.2%), dyslipidemia (29.7%) and diabetes (17%). During available period, 70% (N = 12,754) had a second-line therapy and 57% (N = 10,394) a third-line therapy, predominantly ophthalmic drugs. As first-line, besides 96.3% patients with ophthalmic drops, a small proportion reported trabeculectomy (3.5%) or trabeculoplasty (0.4%). Adherence to ophthalmic drops was found in 58.3% patients and therapy persistence reached 78.1%. Mean total annual cost per patient was €1,725, mostly due to all-cause drug expenditure (€800), all-cause hospitalizations (€567) and outpatient services (€359). In conclusion, glaucoma-treated patients were mostly in monotherapy ophthalmic medications, with an unsatisfying adherence and persistence (<80%). Drug expenditures were the weightiest item among healthcare costs. These real-life data suggest that further efforts are needed to optimize glaucoma management.
format Online
Article
Text
id pubmed-10001280
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100012802023-03-11 Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy Perrone, Valentina Formica, Dario Piergentili, Benedetta Rossetti, Luca Degli Esposti, Luca Healthcare (Basel) Article This real-world analysis was performed on administrative databases to evaluate characteristics, therapies, and related economic burden of glaucoma in Italy. Adults with at least 1 prescription for ophthalmic drops (ATC class S01E: antiglaucoma preparations, miotics) during data availability period (January 2010−June 2021) were screened, then patients with glaucoma were included. First date of ophthalmic drops prescription was the index date. Included patients had at least 12 months of data availability before index-date and afterwards. Overall, 18,161 glaucoma-treated patients were identified. The most frequent comorbidities were hypertension (60.2%), dyslipidemia (29.7%) and diabetes (17%). During available period, 70% (N = 12,754) had a second-line therapy and 57% (N = 10,394) a third-line therapy, predominantly ophthalmic drugs. As first-line, besides 96.3% patients with ophthalmic drops, a small proportion reported trabeculectomy (3.5%) or trabeculoplasty (0.4%). Adherence to ophthalmic drops was found in 58.3% patients and therapy persistence reached 78.1%. Mean total annual cost per patient was €1,725, mostly due to all-cause drug expenditure (€800), all-cause hospitalizations (€567) and outpatient services (€359). In conclusion, glaucoma-treated patients were mostly in monotherapy ophthalmic medications, with an unsatisfying adherence and persistence (<80%). Drug expenditures were the weightiest item among healthcare costs. These real-life data suggest that further efforts are needed to optimize glaucoma management. MDPI 2023-02-21 /pmc/articles/PMC10001280/ /pubmed/36900638 http://dx.doi.org/10.3390/healthcare11050635 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Perrone, Valentina
Formica, Dario
Piergentili, Benedetta
Rossetti, Luca
Degli Esposti, Luca
Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy
title Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy
title_full Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy
title_fullStr Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy
title_full_unstemmed Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy
title_short Real-World Analysis on the Characteristics, Therapeutic Paths and Economic Burden for Patients Treated for Glaucoma in Italy
title_sort real-world analysis on the characteristics, therapeutic paths and economic burden for patients treated for glaucoma in italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001280/
https://www.ncbi.nlm.nih.gov/pubmed/36900638
http://dx.doi.org/10.3390/healthcare11050635
work_keys_str_mv AT perronevalentina realworldanalysisonthecharacteristicstherapeuticpathsandeconomicburdenforpatientstreatedforglaucomainitaly
AT formicadario realworldanalysisonthecharacteristicstherapeuticpathsandeconomicburdenforpatientstreatedforglaucomainitaly
AT piergentilibenedetta realworldanalysisonthecharacteristicstherapeuticpathsandeconomicburdenforpatientstreatedforglaucomainitaly
AT rossettiluca realworldanalysisonthecharacteristicstherapeuticpathsandeconomicburdenforpatientstreatedforglaucomainitaly
AT degliespostiluca realworldanalysisonthecharacteristicstherapeuticpathsandeconomicburdenforpatientstreatedforglaucomainitaly